Go to content
UR Home

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study

Lamers, Leida M., Stupp, Roger, van den Bent, Martin J., Al, Maiwenn J., Gorlia, Thierry, Wasserfallen, Jean-Blaise, Mittmann, Nicole, Jin Seung, Soo, Crott, Ralph and Uyl-de Groot, Carin A. (2008) Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer 112 (6), pp. 1337-1344.

Full text not available from this repository.

at PubMed

at publisher (via DOI)


Abstract

The ICER of euro37,361 per life-year gained is a conservative estimate. We concluded that despite the high TMZ acquisition costs, the costs per life-year gained are comparable to accepted first-line treatment with chemotherapy in patients with cancer.


Export bibliographical data



Item type:Article
Date:2008
Additional Information (public):EORTC 26981/22981 NCI-C CE3 Intergroup Study
Institutions:Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Identification Number:
ValueType
18213621PubMed ID
10.1002/cncr.23297DOI
Classification:
NotationType
AdolescentMESH
AdultMESH
AgedMESH
Antineoplastic Agents, Alkylating/therapeutic useMESH
Brain Neoplasms/radiotherapyMESH
Cost-Benefit AnalysisMESH
Dacarbazine/therapeutic useMESH
Disease-Free SurvivalMESH
Follow-Up StudiesMESH
Glioblastoma/radiotherapyMESH
Health Care CostsMESH
HumansMESH
Middle AgedMESH
Quality-Adjusted Life YearsMESH
Survival RateMESH
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Unknown
Item ID:29325
Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons